Stock price graph

Transfer Agent

Wells Fargo Bank, N.A.
P.O. Box 64874 St. Paul, MN 55164-0874
(800) 468-9716

SIGN UP FOR Email Alerts

Automatically receive financial and general information.
Subscribe Now »

KYTHERA is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel prescription products for the aesthetic medicine market. Our objective is to develop first-in-class, prescription products using an approach that relies on the scientific rigor of biotechnology to address unmet needs in the rapidly-growing market for aesthetic medicine. Our initial focus is on the facial aesthetics market, which comprises the majority of the aesthetic medicine market. Our product candidate, ATX-101, is a potential first-in-class, injectable drug currently in Phase III clinical development for the reduction of submental fat, which commonly presents as an undesirable "double chin." We maintain an active research interest in hair and fat biology, pigmentation modulation and facial contouring. In addition, we expect to assess future potential treatment indications for ATX-101 in the body with high aesthetic value.

View all »   RSSRecent Releases

Jan 23, 2015
KYTHERA Biopharmaceuticals Announces Date of FDA Advisory Committee Review of ATX-101 for the Treatment of Submental Fullness

Jan 20, 2015
KYTHERA Biopharmaceuticals Grants Stock Options Under Inducement Program